Sanofi, tolebrutinib
The totality of data from Sanofi clinical trials indicates that Tolebrutinib may target inflammation thought to contribute to ...
Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...
The FDA approved Sanofi's Sarclisa (isatuximab) in combination with VRd as a first-line treatment for newly diagnosed ...
Sanofi Chief Executive Paul Hudson said on Monday that the company has not made a final decision yet on how it plans to split ...
The primary endpoint of the study is the effect of masitinib on time to confirmed disability progression. The recent results of tolebrutinib in non-active secondary progressive MS presented at the ...
The Bruton's tyrosine kinase inhibitor tolebrutinib is reportedly the first agent to show benefit in patients with nonrelapsing secondary progressive MS.
Sanofi/Sclérose en plaques-Le tolebrutinib allonge de 31% le délai avant progression du handicap Sanofi a annoncé vendredi que le tolebrutinib, son candidat-médicament le plus avancé contre la ...